James H. Mackaness - Oct 2, 2023 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role
Chief Financial Officer
Signature
/s/ James Mackaness
Stock symbol
SLNO
Transactions as of
Oct 2, 2023
Transactions value $
$22,000
Form type
4
Date filed
12/13/2023, 09:32 PM
Previous filing
May 26, 2023
Next filing
Nov 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLNO Common Stock Options Exercise $12K +2.67K +7.94% $4.50* 36.2K Oct 2, 2023 Direct F1
transaction SLNO Common Stock Options Exercise $3.75K +2.14K +5.91% $1.75* 38.4K Oct 2, 2023 Direct F1
transaction SLNO Common Stock Options Exercise $8.75K +3.5K +9.12% $2.50* 41.9K Oct 2, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLNO Warrants (right to buy) Options Exercise $0 -2.67K -100% $0.00* 0 Oct 2, 2023 Common Stock 2.67K $4.50 Direct
transaction SLNO Warrants (right to buy) Options Exercise -$948 -2.14K -100% $0.44 0 Oct 2, 2023 Common Stock 2.14K $1.75 Direct F2
transaction SLNO Warrants (right to buy) Options Exercise -$1.55K -3.5K -100% $0.44 0 Oct 2, 2023 Common Stock 3.5K $2.50 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of shares reported as beneficially owned following the reported transaction is as of October 2, 2023.
F2 The Warrants expire upon the earlier of (i) 30 days following announcement of positive top-line data from the randomized withdrawal period of Study C602, an open-label extension study pertaining to Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS), or (ii) November 8, 2026.
F3 The Warrants expire upon the earlier of (i) 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS or (ii) November 8, 2026.